Octreotide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Octreotide acetate injection · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The label covers reduction of growth hormone and IGF-1 in specified acromegaly settings, diarrhea and flushing with metastatic carcinoid tumors, and diarrhea with VIP-secreting tumors. It says the cited injection trials did not establish reduction in tumor size or growth; this is separate from evidence for other formulations. Label: 1 ↗
Which safety limits matter?
The label contraindicates hypersensitivity and warns about cardiac conduction abnormalities, gallstones and complications, altered glucose control, hypothyroidism, and impaired fat absorption. Intravenous administration has a distinct warning about higher-degree heart block. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02
Label ZIP SHA-256: ef983a96082e22365e0421c84727fd1f1c4edba8f562651f80efe7222ff70491. Extracted XML SHA-256: 14384962a14328e523de4f1f393ab757985c463cef9f2e690b3b8491076f76d7.